Kenneth Bloom, MD, FCAP is the Head of Pathology at Nucleai. He has over 35 years of experience in pathology, oncology, telemedicine, and bioinformatics. Dr. Bloom has held several leadership positions, including CMO at REALM IDx and President and Head of Oncology & Immunotherapy for Human Longevity Inc, CMO for In Vitro Diagnostics at GE Healthcare, co-founder, CMO and Medical Director of Clarient. Prior to his industry experience, he spent 15 years at Rush Medical Center, where he helped design and implement the first telepathology system. He has also been a Clinical Professor of Pathology at the University of Southern California. Dr. Bloom has been the principal investigator on over a dozen clinical trials and has served as an advisor to many pharmaceutical and biotechnology companies. He received his M.D. from Rush Medical College and his B.A. from Grinnell College.
AI and Data Sciences Showcase:
Nucleai developed an AI-powered pathology-based biomarker discovery platform to unlock the power of spatial biology from pathology images. Leveraging computer vision and deep neural networks to structure and characterize tissue and cell architecture, identifying spatial characteristics that predict response to therapy and inform treatment decisions.
AI driven spatial biology, the next NGS
There is a wealth of data ready to be unlocked from pathology slides
The PMWC 2023 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.